APA (7th ed.) Citation

Iliev, P., Jaworski, C., Wängler, C., Wängler, B., Page, B. D. G., Schirrmacher, R., & Bailey, J. J. (2024). Type II & III inhibitors of tropomyosin receptor kinase (Trk): A 2020-2022 patent update. Expert opinion on therapeutic patents, 34(4), . https://doi.org/10.1080/13543776.2024.2358818

Chicago Style (17th ed.) Citation

Iliev, Petar, Carolin Jaworski, Carmen Wängler, Björn Wängler, Brent D. G. Page, Ralf Schirrmacher, and Justin J. Bailey. "Type II & III Inhibitors of Tropomyosin Receptor Kinase (Trk): A 2020-2022 Patent Update." Expert Opinion on Therapeutic Patents 34, no. 4 (2024). https://doi.org/10.1080/13543776.2024.2358818.

MLA (9th ed.) Citation

Iliev, Petar, et al. "Type II & III Inhibitors of Tropomyosin Receptor Kinase (Trk): A 2020-2022 Patent Update." Expert Opinion on Therapeutic Patents, vol. 34, no. 4, 2024, https://doi.org/10.1080/13543776.2024.2358818.